IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Richard Belanger who wrote (1728)	12/26/2000 9:16:50 PM
From: Maurice Winn	1 Recommendation of 1762

Anti CD20 antibodies such as Rituxan and purine analogues are synergistic against lymphoma. www3.interscience.wiley.com <Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies S. A. Johnson , W. Thomas Department of Haematology, Taunton & Somerset Hospital, Taunton, Somerset, UK email: S. A. Johnson (s.a.johnson@btinternet.com) Correspondence to S. A. Johnson, Taunton and Somerset Hospital, Taunton TA1 5DA, Somerset, UK. Keywords fludarabine; cladribine; combination therapy; lymphoma; lymphoproliferative disease Abstract The main purine analogues with activity against lymphoid malignancies are fludarabine, cladribine and pentostatin, all of which are active against slowly proliferating cells through their inhibition of DNA repair and therefore have significant synergistic activity with cytotoxic agents which cause DNA damage. Combinations of purine analogues and alkylating agents or platinum compounds result in markedly increased activity but at the expense of more severe haematological toxicity, while evidence of synergy with anthracyclines/anthracenediones is apparent in the treatment of malignant lymphoma. Interaction between fludarabine or cladribine with deoxycytidine kinase results in a significant enhancement of the activity of cytarabine. Unexpected evidence of clinical synergy is also apparent in combinations of purine analogues and anti-CD20 monoclonal antibodies. Copyright © 2000 John Wiley & Sons, Ltd. > Not new <Received: 20 June 2000; Revised: 15 August 2000; Accepted: 21 August 2000 > but of interest. Published online, 19 Dec Y2K. Mqurice PS: Rich, still coming back to your comments. Need a break [again].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next